The Room Where It Happens: A Skeptic's Analysis of the New Heart Failure Guidelines

Journal of Cardiac Failure

Volumn 22, Issue 9, 2016, Pages 726-730

  Packer, Milton ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Guidelines

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IVABRADINE; MINERALOCORTICOID ANTAGONIST; ANTIARRHYTHMIC AGENT; DIURETIC AGENT;

ARTICLE; CLINICAL DECISION MAKING; CLINICAL EVALUATION; EVIDENCE BASED MEDICINE; HEART FAILURE; HUMAN; OUTCOME ASSESSMENT; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT INDICATION; DRUG EFFECTS; EUROPE; EVALUATION STUDY; FEMALE; HEALTH PERSONNEL ATTITUDE; HEART STROKE VOLUME; MALE; MORTALITY; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STANDARDS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; ATTITUDE OF HEALTH PERSONNEL; DIURETICS; EUROPE; FEMALE; HEART FAILURE; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 84990888730     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2016.07.433     Document Type: Article

References (27)

1. 1 Ponikowski, P., Voors, A.A., Anker, S.D., Bueno, H., Cleland, J.G.F., Coats, A.J.S., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. on behalf of; Authors/Task Force Members Eur Heart J 37 (2016), 2129–2200 pii: ehw128; Epub ahead of print.
2. 2 Yancy, C.W., Jessup, M., Bozkurt, B., Butler, J., Casey, D.E., Colvin, M.M., et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Developed in collaboration with the international society for heart and lung transplantation. Circulation, 2016, 10.1161/CIR.0000000000000435 published online before print May 20, 2016.
3. 3 McMurray, J.J., Adamopoulos, S., Anker, S.D., Auricchio, A., Böhm, M., Dickstein, K., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14 (2012), 803–869.
4. 4 Yancy, C.W., Jessup, M., Bozkurt, B., Butler, J., Casey, D.E. Jr, Drazner, M.H., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128 (2013), e240–327.
5. 5 Packer, M., Unbelievable folly of clinical trials in heart failure: the inconvenient truth about how investigators and guidelines weigh evidence. Circ Heart Fail, 9, 2016 pii: e002837.
6. 6 Nadruz, W. Jr, West, E., Santos, M., Skali, H., Groarke, J.D., Forman, D.E., et al. Heart failure and midrange ejection fraction: implications of recovered ejection fraction for exercise tolerance and outcomes. Circ Heart Fail, 9, 2016, e002826, 10.1161/CIRCHEARTFAILURE.115.002826.
7. 7 Packer, M., Gheorghiade, M., Young, J.B., Costantini, P.J., Adams, K.F., Cody, R.J., et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 329 (1993), 1–7.
8. 8 Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336 (1997), 525–533.
9. 9 Swedberg, K., Komajda, M., Böhm, M., Borer, J.S., Ford, I., Dubost-Brama, A., et al. Ivabradine and Outcomes in Chronic Heart Failure (SHIFT): a randomised placebo-controlled study. Lancet 376 (2010), 875–885.
10. 10 Fox, K., Ford, I., Steg, P.G., Tendera, M., Ferrari, R., BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372 (2008), 807–816.
11. 11 Fox, K., Ford, I., Steg, P.G., Tardif, J.C., Tendera, M., Ferrari, R., et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 371 (2014), 1091–1099.
12. 12 Adams, K.F. Jr, Patterson, J.H., Gattis, W.A., O'Connor, C.M., Lee, C.R., Schwartz, T.A., et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol 46 (2005), 497–504.
13. 13 Fox, K., Komajda, M., Ford, I., Robertson, M., Böhm, M., Borer, J.S., et al. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. Eur Heart J 34 (2013), 2263–2270.
14. 14 Lapostolle, F., Borron, S.W., Verdier, C., Arnaud, F., Couvreur, J., Mégarbane, B., et al. Assessment of digoxin antibody use in patients with elevated serum digoxin following chronic or acute exposure. Intensive Care Med 34 (2008), 1448–1453.
15. 15 van Veldhuisen, D.J., Man in ‘t Veld, A.J., Dunselman, P.H., Lok, D.J., Dohmen, H.J., Poortermans, J.C., et al. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT). J Am Coll Cardiol 22 (1993), 1564–1573.
16. 16 Garg, R., Yusuf, S., Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 273 (1995), 1450–1456.
17. 17 SOLVD Investigators, Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991), 293–302.
18. 18 CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 (1987), 1429–1435.
19. 19 Konstam, M.A., Neaton, J.D., Dickstein, K., Drexler, H., Komajda, M., Martinez, F.A., et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 374 (2009), 1840–1848.
20. 20 Hauptman, P.J., All clinical trials are not created equal: the dilemma of HEAAL. Eur J Heart Fail 10 (2008), 817–818.
21. 21 Granger, C.B., McMurray, J.J., Yusuf, S., Held, P., Michelson, E.L., Olofsson, B., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362 (2003), 772–776.
22. 22 McMurray, J.J., Packer, M., Desai, A.S., Gong, J., Lefkowitz, M.P., Rizkala, A.R., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. for the; PARADIGM-HF Investigators and Committees N Engl J Med 371 (2014), 993–1004.
23. 23 Fitchett, D., Zinman, B., Wanner, C., Lachin, J.M., Hantel, S., Salsali, A., et al. EMPA-REG OUTCOME® trial investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J 37 (2016), 1526–1534.
24. 24 MacDonald, M.R., Eurich, D.T., Majumdar, S.R., Lewsey, J.D., Bhagra, S., Jhund, P.S., et al. Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. Diabetes Care 33 (2010), 1213–1218.
25. 25 Jankowska, E.A., Kasztura, M., Sokolski, M., Bronisz, M., Nawrocka, S., Oleśkowska-Florek, W., et al. Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. Eur Heart J 35 (2014), 2468–2476.
26. 26 Ponikowski, P., van Veldhuisen, D.J., Comin-Colet, J., Ertl, G., Komajda, M., Mareev, V., et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 36 (2015), 657–668.
27. 27 Anker, S.D., Comin Colet, J., Filippatos, G., Willenheimer, R., Dickstein, K., Drexler, H., et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361 (2009), 2436–2448.